NTT: CEOs See Major Opportunities in Emerging Technologies to Tackle Social Challenges
18.12.2020 07:18:00 EET | Business Wire | Press release
WSJ Intelligence undertook a new international CEO survey for global technology and business solution provider NTT (TOKYO:9432). The survey focused on the dire necessity for complex digital technologies that have made it possible for businesses and societies to keep functioning amid the Covid-19 global pandemic.
WSJ Intelligence's global survey included 352 CEOs of large corporations representing ten major industries, across fifteen countries. The CEOs surveyed were asked about their corporation's role in society, their social-impact strategies, the stakeholders involved, and how those strategies were affected by the pandemic. This survey also examined the CEOs' confidence in a range of new and emerging technologies, and how those innovations might help the world to tackle enormous social challenges, such as the global supply chain, the future of work and health and well-being.
Key Findings:
- 56% of respondents believe corporations generate value by earning profits in a sustainable way that includes minimizing harm to society;
- 80% of stakeholder-centric executives say they pursue parallel financial and community outcomes, and see social-impact strategies as essential to financial returns;
- Technology powers the tools and opportunities to tackle social issues, but can also disrupt social stability through the rapid spread of false or misleading information;
- Cybersecurity is the only technology that a majority of executives consider fully adequate for their social-impact strategy; however adoption of cybersecurity technologies is not fast enough or sufficiently complete yet
- High-performance communications networks, followed by cloud computing and advanced analytics, are identified by CEOs as promising technologies with which to address social issues.
As the world continues to combat Covid-19 and plan for recovery, digital technology and social-impact programs will help to create the "new normal." The recovery from Covid-19 presents every organization with the opportunity to think in new ways and accelerate digital transformation.
About This Research
This research was conducted in July/August 2020 among CEOs across 15 countries, who participated in an online survey that aimed to understand how they viewed their company's responsibility to contribute, visibly and substantively, to achieving societal goals. Globally, 352 CEOs at companies with more than US$500M in revenue (with 75 of U.S. respondents at companies with more than $1BN) participated in quantitative research across 10 industries. "Investor-centric" respondents were defined as those whose view of the corporation is strictly to create value for shareholders by earning profit. "Stakeholder-centric" respondents answered either: "To create value for all stakeholders by earning profits in a sustainable way, which includes minimizing the harm that the business causes to society" or "Contribute to solutions for the challenges confronting people and society as a means of earning profits and generating long-term stakeholder value", when asked for their view of the role of the corporation in global society today.
[Reference]
READ THE WHITE PAPER (PDF: 2MB)
About WSJ Intelligence
WSJ Intelligence conducts bespoke and secondary research for brands and client brands of The Wall Street Journal | Barron's Group. Through rigorous analysis, WSJ Intelligence provides insights that are relevant, timely, and reliable.
About NTT
NTT believes in contributing to society through our business operations. We help people, clients and communities move confidently into the digital future and shape a better world. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data centers and networks. As a top-5 global technology and business solutions provider, our diverse team of over 300,000 people operates in 80+ countries and regions and delivers services to over 190 of them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217006234/en/
Contact information
Yuzo Aramaki
Associate Manager
Press Relations of NTT Corporation
Mail: ntt-cnr-ml@hco.ntt.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
